Daniel Brennan

Subbu Nambi

Subhalaxmi Nambi

Yuko Oku

Elizabeth Koslosky

Jason Lai

Matthew Stanton

Matthew Sykes

- Nautilus Biotechnology reported a **net loss of $13.6 million** for Q3 2025, an improvement from $16.4 million in the prior year, with total operating expenses decreasing to **$15.5 million** from $19.1 million.  **[0001808805_2207852_5]** 
- The company ended Q3 2025 with **$168.5 million in cash**, cash equivalents, and investments, and a cash burn of **$11.0 million** for the quarter, projecting a cash runway extending **through 2027**.  **[0001808805_2207852_5]** 
- Nautilus plans to launch its **early access program in the first half of 2026**, starting with the TAU proteoform assay, and anticipates a broad-scale commercial launch by the **end of 2026**.  **[0001808805_2207852_2]** **[0001808805_2207852_6]** **[0001808805_2207852_7]** 
- Market research indicates customers view the Nautilus platform as **uniquely differentiated** and are willing to pay a **premium** for its capabilities, reinforcing confidence in the commercial opportunity.  **[0001808805_2207852_4]** **[0001808805_2207852_6]** 
- While Q3 2025 was a **low point in spending**, the company expects operating expenses to **increase in future quarters** as product and market development activities ramp up towards commercialization.  **[0001808805_2207852_5]** **[0001808805_2207852_6]**

Nautilus Biotechnology Reports Q3 2025 Financial Results and Outlines Commercialization Plans

- Nautilus Biotechnology reported a **net loss of $13.6 million** for Q3 2025, an improvement from **$16.4 million** in Q3 2024, with total operating expenses decreasing **19%** year-over-year to **$15.5 million**.  **[0001808805_2211687_5]** 
- The company ended Q3 2025 with **$168.5 million** in cash, cash equivalents, and investments, and projects a cash runway extending **through 2027**.  **[0001808805_2211687_5]** 
- Nautilus plans to launch its early access program in the **first half of 2026**, starting with the Tau proteoform assay, and anticipates a broad-scale commercial launch in **late 2026**.  **[0001808805_2211687_2]** **[0001808805_2211687_4]** **[0001808805_2211687_6]** **[0001808805_2211687_7]** 
- Management expects Q3 2025 to be a low point in spending, with operating expenses anticipated to increase in future quarters as product and market development activities ramp up, and does not expect meaningful services revenue from early access engagements in 2026.  **[0001808805_2211687_5]** **[0001808805_2211687_6]**

Nautilus Biotechnology Reports Q3 2025 Financial Results and Commercialization Progress

- Nautilus Biotechnology reported **Q3 2025 operating expenses of $15.5 million**, representing a **19% year-over-year decrease**, and a **net loss of $13.6 million**.  **[0001808805_2211627_5]** 
- The company ended Q3 2025 with **$168.5 million in cash, cash equivalents, and investments**, with a **cash burn of $11.0 million** for the quarter, and projects a **cash runway extending through 2027**.  **[0001808805_2211627_5]** 
- The **early access program for the TAU proteoform assay is scheduled to launch in the first half of 2026**, with a **broad-scale commercial launch anticipated in late 2026**.  **[0001808805_2211627_2]** **[0001808805_2211627_7]** 
- Market research involving over 250 decision makers indicated that customers view the Nautilus platform as **uniquely differentiated**, are **willing to pay a premium**, and are **eager to engage** with the technology.  **[0001808805_2211627_4]** 
- The company made progress on its TAU proteoform assay, including collaborations with the Allen Institute for Brain Science and the Buck Institute for Research on Aging, and transitioned to a new broad-scale assay configuration.  **[0001808805_2211627_1]** **[0001808805_2211627_2]**

Nautilus Biotechnology Reports Q3 2025 Results and Outlines Commercialization Plans

- Nautilus Biotechnology reported a **net loss of $13.6 million** for the third quarter ended September 30, 2025, compared to a net loss of $16.4 million for the corresponding prior year period.  **[1808805_0a0fae7fe3e24f4ba3725816b324401e_1]** 
- Operating expenses for Q3 2025 were **$15.5 million**, a **19% decrease** from $19.1 million in the same period last year, driven by operating efficiencies, lower development costs, and reduced salaries and benefits.  **[1808805_0a0fae7fe3e24f4ba3725816b324401e_1]** 
- As of September 30, 2025, the company's cash, cash equivalents, and investments totaled **$168.5 million**.  **[1808805_0a0fae7fe3e24f4ba3725816b324401e_1]** 
- The company anticipates launching its early access program with Tau proteoforms in the **first half of 2026**, with the full commercial launch expected in **late 2026**.  **[1808805_0a0fae7fe3e24f4ba3725816b324401e_0]** **[1808805_0a0fae7fe3e24f4ba3725816b324401e_1]**

Nautilus Biotechnology Reports Third Quarter 2025 Financial Results

- Nautilus Biotechnology reported a **net loss of $13.6 million** for the third quarter of 2025, an improvement from a net loss of $16.4 million in the prior year period.  **[1808805_0001808805-25-000077_exhibit991-q3258xkearnings.htm:0]** 
- Operating expenses for Q3 2025 decreased by **19% to $15.5 million**, down from $19.1 million in the corresponding prior year period, primarily due to operating efficiencies, lower development-related costs, and decreased compensation.  **[1808805_0001808805-25-000077_exhibit991-q3258xkearnings.htm:0]** 
- As of September 30, 2025, the company held **$168.5 million** in cash, cash equivalents, and investments.  **[1808805_0001808805-25-000077_exhibit991-q3258xkearnings.htm:0]** 
- Nautilus expects to launch its early access program with Tau proteoforms in the **first half of 2026**, with the full commercial launch of its new broadscale assay format anticipated in **late 2026**.  **[1808805_0001808805-25-000077_exhibit991-q3258xkearnings.htm:0]**

- Nautilus Biotechnology is developing a **disruptive iterative mapping platform** to address the inefficiencies in drug development by providing a new approach to protein measurement, with a market projected to reach **$57 billion by 2030**.  **[1808805_2145740_1]** **[1808805_2145740_4]** **[1808805_2145740_7]** 
- The company plans to launch its platform in **late 2026**, with the instrument priced at **$1 million** and consumables designed to generate **$1 million in pull-through over time**.  **[1808805_2145740_7]** 
- Nautilus reported **$180 million** in cash on its balance sheet in Q2, anticipating these funds will last through **2027**, and has reduced operating expenses by approximately **20% year-over-year**.  **[1808805_2145740_7]** 
- Founders maintain significant ownership, holding **32%** of the company, indicating strong alignment with shareholder interests.  **[1808805_2145740_8]**

Nautilus Biotechnology (NAUT)